Neurofilament Light Chain (NfL) serves as a highly sensitive biomarker of neuroaxonal injury across neurodegenerative diseases. Elevated NfL levels in cerebrospinal fluid (CSF) and blood indicate ongoing axonal damage, making it an ideal therapeutic target for neuroprotective interventions. NfL reduction therapy aims to preserve neuronal integrity and slow disease progression by targeting the underlying mechanisms that cause axonal injury.
NfL is a structural protein of the neuronal cytoskeleton that is released into the extracellular space following axonal injury or neuronal death. Key characteristics:
Mechanism: Impaired energy production leads to axonal degeneration
Therapeutic approaches:
NfL outcome: Expected 20-40% reduction with effective treatment
Mechanism: Reactive oxygen species damage neuronal membranes and cytoskeleton
Therapeutic approaches:
NfL outcome: Stabilization of NfL levels (prevention of rise)
Mechanism: Excessive glutamate signaling leads to calcium overload and axonal damage
Therapeutic approaches:
NfL outcome: Reduction in NfL elevation rate
Mechanism: Inflammatory mediators cause secondary axonal damage
Therapeutic approaches (see also Neuroinflammation Modulation:
NfL outcome: 15-30% reduction when inflammation is controlled
Mechanism: Misfolded proteins (tau, α-synuclein, TDP-43) disrupt axonal transport
Therapeutic approaches:
NfL outcome: Variable reduction depending on aggregate clearance
| Drug | Primary Target | Phase | NfL Endpoint | Expected Effect |
|---|---|---|---|---|
| Coenzyme Q10 | Mitochondrial function | Phase 3 (ALS) | CSF NfL | 20-30% reduction |
| Treamidine | Neuroprotection | Phase 2 (PD) | Plasma NfL | Stabilization |
| CNM-Au8 | Mitochondrial function | Phase 2 (PD/ALS) | Serum NfL | 15-25% reduction |
| Minozac | Microglial activation | Phase 2 (AD) | CSF NfL | Stabilization |
| Rapamycin | Autophagy | Phase 2 (AD) | Plasma NfL | 10-20% reduction |
| NfL Level | Interpretation | Treatment Approach |
|---|---|---|
| Normal | No significant axonal injury | Preventive strategies |
| Mildly elevated | Early axonal injury | Aggressive disease-modifying |
| Moderately elevated | Active neurodegeneration | Combination therapy |
| Highly elevated | Advanced disease | Symptomatic + neuroprotective |
| Time Point | Assessments | Clinical Decision |
|---|---|---|
| Baseline | NfL, clinical measures | Treatment selection |
| Month 1 | Plasma NfL | Early response assessment |
| Month 3 | Plasma NfL, safety | Dose adjustment |
| Month 6 | Plasma NfL, CSF NfL | Formal response assessment |
| Month 12 | Comprehensive panel | Long-term efficacy |
Goal: Protect axons from injury regardless of upstream trigger
Approaches:
Biomarker response: 15-35% NfL reduction
Goal: Maintain ATP levels in vulnerable axons
Approaches:
Biomarker response: 20-40% NfL reduction
Goal: Prevent inflammation-mediated axonal damage
Approaches:
Biomarker response: 15-30% NfL reduction
Goal: Remove toxic aggregates while protecting axons
Approaches:
Biomarker response: Variable; depends on aggregate clearance
NfL elevation often results from multiple mechanisms. Combination therapy addressing several pathways may provide greater NfL reduction:
| Combination | Rationale | NfL Target |
|---|---|---|
| CoQ10 + Minocycline | Mito + anti-inflammatory | 30-50% reduction |
| Anti-tau + TREM2 agonist | Clear tau + modulate microglia | 25-40% reduction |
| NAD+ booster + rapamycin | Energy + autophagy | 20-35% reduction |
Major responder: >30% reduction in NfL from baseline
Partial responder: 15-30% reduction in NfL
Non-responder: <15% reduction or increase in NfL